A Phase 1 Study to Assess Mass Balance, Pharmacokinetics, and Metabolism of Orally Administered [14 C]-TAK-659 in Patients With Advanced Solid Tumor and/or Lymphoma Malignancies
Status: Withdrawn prior to enrolment
Phase of Trial: Phase I
Latest Information Update: 04 Apr 2018
Price : $35 *
At a glance
- Drugs Mivavotinib (Primary) ; Mivavotinib (Primary)
- Indications Lymphoma; Solid tumours
- Focus Pharmacokinetics
- Sponsors Takeda Oncology
- 26 Mar 2018 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 26 Jan 2018 Planned End Date changed from 11 Jun 2019 to 1 May 2019.
- 26 Jan 2018 Planned primary completion date changed from 29 Dec 2017 to 1 May 2019.